Winst gevend schreef op 28 mei 2020 18:32:
Van Leeuwenhoeck In.
US-based Biocryst (NASDAQ: BCRX)
is awaiting FDA approval for berotralstat for prophylactic use in HAE (PDUFA date 3 December 2020).
In our view, Biocryst would be an ideal M&A candidate for Pharming due to:
• Access to an orally-administered drug for prophylactic use in HAE
• Gaining market share in HAE market for prophylactic use
• Synergies in the use of existing commercial infrastructure in the US
• Increased near term profitability
Niet een beetje te duur voor Pharming dan?